Literature DB >> 12142032

T cell antigen receptor (TCR) transmembrane peptides colocalize with TCR, not lipid rafts, in surface membranes.

Xin M Wang1, Julianne T Djordjevic, Veronica Bender, Nicholas Manolios.   

Abstract

We have previously shown that a synthetic peptide termed core peptide (CP), which corresponds to a sequence within the transmembrane domain of the alpha chain of the T cell antigen receptor (TCR), can inhibit IL-2 production in antigen-stimulated T cells and can suppress inflammation in several T cell-mediated animal models of disease. As the first step in determining the mechanism of CP action, we examined the association of CP with the plasma membrane of human T cells using confocal microscopy. A homogeneous distribution of CP was observed in the plasma membrane of human T cells. This membrane localization was dependent on the presence of positive charges in the CP sequence. CP analogs, containing either neutral or negatively charged amino acids in place of the positive amino acid charges, did not localize within TCR membranes. Following antibody-induced TCR clustering, there was specific colocalization of CP with surface TCR. No association was observed with other cell surface receptors when similarly clustered. Since TCR activation leads to an increased movement of the receptor complex to cholesterol/glycosphingolipid (GSL) plasma membrane microdomains (rafts) we examined whether the association of CP with TCR was raft-driven. TCR clustering led only to a partial colocalization of TCRs with raft GSL, ganglioside GM1, and a complete colocalization of CP with TCRs. We conclude that CP associates specifically with plasma membrane TCRs and not raft lipids.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142032     DOI: 10.1016/s0008-8749(02)00002-3

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  14 in total

1.  Transmembrane T-cell receptor peptides inhibit B- and natural killer-cell function.

Authors:  Nghi T Huynh; Rosemary A Ffrench; Ross A Boadle; Nicholas Manolios
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

Review 2.  New therapeutic strategies targeting transmembrane signal transduction in the immune system.

Authors:  Alexander B Sigalov
Journal:  Cell Adh Migr       Date:  2010-04-24       Impact factor: 3.405

3.  The SCHOOL of nature: III. From mechanistic understanding to novel therapies.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-06-11

4.  The SCHOOL of nature: IV. Learning from viruses.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-10

5.  A GxxxG-like motif within HIV-1 fusion peptide is critical to its immunosuppressant activity, structure, and interaction with the transmembrane domain of the T-cell receptor.

Authors:  Omri Faingold; Tomer Cohen; Yechiel Shai
Journal:  J Biol Chem       Date:  2012-08-07       Impact factor: 5.157

Review 6.  T-cell antigen receptor (TCR) transmembrane peptides: A new paradigm for the treatment of autoimmune diseases.

Authors:  Nicholas Manolios; Marina Ali; Vera Bender
Journal:  Cell Adh Migr       Date:  2010-04-30       Impact factor: 3.405

7.  Novel TREM-1 Inhibitors Attenuate Tumor Growth and Prolong Survival in Experimental Pancreatic Cancer.

Authors:  Zu T Shen; Alexander B Sigalov
Journal:  Mol Pharm       Date:  2017-11-13       Impact factor: 4.939

8.  HIV-1 gp41 and TCRalpha trans-membrane domains share a motif exploited by the HIV virus to modulate T-cell proliferation.

Authors:  Tomer Cohen; Shmuel Jaffe Cohen; Niv Antonovsky; Irun R Cohen; Yechiel Shai
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

9.  Novel mechanistic insights into viral modulation of immune receptor signaling.

Authors:  Alexander B Sigalov
Journal:  PLoS Pathog       Date:  2009-07-31       Impact factor: 6.823

10.  SARS Coronavirus Fusion Peptide-Derived Sequence Suppresses Collagen-Induced Arthritis in DBA/1J Mice.

Authors:  Zu T Shen; Alexander B Sigalov
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.